id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1978-N-0022-0021,FDA,FDA-1978-N-0022,"Answer from FDA/CDER to Letter from AAC Consulting Group, Inc. to FDA/CDER",Other,Answer,2006-05-25T04:00:00Z,2006,5,,,2020-02-04T13:36:35Z,,0,0,090000648055eca0
FDA-1978-N-0022-0023,FDA,FDA-1978-N-0022,Letter from FDA/CDER to Bayer Corporation,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2020-02-04T13:39:10Z,,0,0,090000648055eca2
FDA-1978-N-0022-0022,FDA,FDA-1978-N-0022,Letter from FDA/CDER to Otis Clapp,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2020-02-04T13:38:23Z,,0,0,090000648055eca1